Company News

Hyperventilation Strain CMR Imaging in Patients With Acute Chest Pain

August 9, 2022
Company News

MORRISVILLE, N.C., August 9, 2022 – MyoStress™, a rapid stress test utilizing breathing maneuvers, has continued to demonstrate excellent accuracy at detecting ischemic coronary artery disease without the need for pharmacologic stress agents or contrast injections in this new publication from University of Heidelberg.

In this article, results comparing MyoStress to high sensitivity troponin and EKG in triaging patients with chest pain in the emergency department reiterated the clinical utility of MyoStress. In detecting ischemia, MyoStress was highly accurate (95.4%) and provided improved benefit over traditional emergency room chest pain protocols. MyoStress has the potential to help reduce crowding in the emergency department by accelerating diagnostic work up in coordination with traditional emergency room chest pain protocols for suspected acute coronary syndrome (ACS).

Conclusion: “Our suggested protocol achieved a high diagnostic accuracy, outperforming other clinical markers for ACS identification. This approach may be particularly useful for ‘troponin observe zone’ patients allowing for a safe, drug-free, and non-invasive assessment of myocardial function.”

 

Access to the publication is available here.

Siry, D., Riffel, J.H., Salatzki, J. et al. Hypverventilation strain CMR imaging in patients with acute chest pain. Sci Rep 12, 13584 (2022). https://doi.org/10.1038/s41598-022-17856-y

Media Contact

PR@myocardialsolutions.com
919.677.8100

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.  

808 Aviation Pkwy, Suite 700 | Morrisville, NC 27560 | myocardialsolutions.com | ph: +1.919.677.8100

© Copyright 2022 Myocardial Solutions Inc. All rights reserved. MyoStrain® and the MyoHealthTM 
Score are among the trademarks of Myocardial Solutions.